| Fecha | Trimestre | Sesión | BPA (est → real) | Ingresos (est → reales) |
|---|---|---|---|---|
| 3 nov 2026Próximo | Q3 2026 | Antes de apertura | 2,98 | 967 M |
1 sept 2026
CRAI gains from strong advisory demand, a diverse client base and specialist talent, but rising costs and tight liquidity pose risks.
Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.
28 ago 2026
27 ago 2026
Opportunities center on non-animal, pharma and regulatory testing, driven by organ-on-chip, organoids, AI biosimulation, genomics and in vitro toxicity platforms.Dublin, Aug. 27, 2026 (GLOBE NEWSWIRE) -- The "Animal Testing and Non-Animal Alternative Testing Global Market Opportunities and Strategies to 2035" has been added to ResearchAndMarkets.com's offering. The latest animal testing and non-animal alternative testing market report provides a comprehensive analysis of industry performance fro
26 ago 2026
Charles River Laboratories has significantly outperformed the market, while strong guidance and a bullish analyst outlook support continued optimism.
25 ago 2026
Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.75% on an annualized basis producing an average annual return of 15.76%. Currently, Charles River has a market capitalization of $15.22
Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
22 ago 2026
Earlier this week, Medigen Vaccine Biologics Corp. announced a collaboration with Charles River Laboratories International to characterize and validate the virus seed bank for its next-generation multivalent enterovirus vaccine, with Charles River providing advanced analytical support including Next-Generation Sequencing for key Chemistry, Manufacturing, and Controls activities. The partnership highlights Charles River’s role as a specialized partner for complex biologics testing and...
Charles River Laboratories International (NYSE:CRL) and Medigen Vaccine Biologics announced a collaboration to develop next-generation enterovirus vaccines using advanced analytics and next-generation sequencing. The partnership focuses on using detailed analytical methods to support faster vaccine development timelines and regulatory compliance. Both companies plan to apply novel testing approaches that aim to reduce reliance on animal studies in future vaccine programs. The agreement is...
21 ago 2026
Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.
Investors need to pay close attention to CRL stock based on the movements in the options market lately.
CRL's shares have surged 88.6% in a year as DSA returns to organic growth, bookings climb and new testing initiatives broaden its strategy.
20 ago 2026
WILMINGTON, Mass., August 20, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) and Medigen Vaccine Biologics Corp. (MVC) collaborate on the characterization and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine. Charles River will leverage its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical steps of Chemistry, Manufacturing, and Controls (CMC) activities for MVC’s next-generation multivalent
Collaboration leverages NGS technologies to accelerate high-quality vaccine development, support global regulatory readiness, and help reduce animal testingCharles River Laboratories International, Inc. (NYSE:CRL) and
19 ago 2026
Opportunities span AI-driven protein design and structure prediction, precision therapeutics, engineered biologics and vaccines, synthetic biology, novel enzymes, high-throughput screening, and advanced computational modeling, with Asia-Pacific offering expansion potential. Protein Design and Engineering Market Protein Design and Engineering Market Dublin, Aug. 19, 2026 (GLOBE NEWSWIRE) -- The "Protein Design and Engineering Market Global Report 2026" has been added to ResearchAndMarkets.com's o
14 ago 2026
Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.07% on an annualized basis producing an average annual return of 15.79%. Currently, Charles River has a market capitalization of $14.32
Charles River Laboratories’ second quarter results were shaped by recovering biopharmaceutical demand and the impact of portfolio streamlining. Management highlighted that the rebound was most evident in the Discovery and Safety Assessment (DSA) segment, where net book-to-bill reached a four-year high and organic revenue growth turned positive for the first time since 2023. CEO Birgit Girshick pointed to an uptick in proposal activity and improved funding for small and midsize biotech clients as
12 ago 2026
Organic revenue returned to growth as biopharmaceutical demand strengthened.
10 ago 2026
Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
TD Cowen analyst Charles Rhyee maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $235 to $300.
7 ago 2026
Morgan Stanley analyst Ricky Goldwasser maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $260 to $300.
6 ago 2026
RBC Capital analyst Ryan Halsted maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $215 to $282.
Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising treatment before the opening bell.
